Meningitis

LexaGene’s MiQLab System Generates Leptospira Results in as Soon as 30 minutes using Isothermal Chemistry

Retrieved on: 
Wednesday, August 24, 2022
Inflammation, Liver failure, CEO, Technology, OTCQB, Advances and Applications in Bioinformatics and Chemistry, LXG, Kidney, Brain, Breathe Me, Death, Culture, Dog, TSX Venture Exchange, Blood, LinkedIn, STAT, Veterinarian, Chemistry, PCR, Leptospira, GLOBE, Intention, Urine, Company, News, Twitter, System, Spinal cord, SEDAR, Growth, Meningitis, Bacteria, CDC, Leptospirosis, Vaccine, Cryptocurrency

Dr. Jack Regan, LexaGenes Founder and CEO stated, Today, we are excited to announce that our innovative, MiQLab System has the capabilities to use isothermal chemistry.

Key Points: 
  • Dr. Jack Regan, LexaGenes Founder and CEO stated, Today, we are excited to announce that our innovative, MiQLab System has the capabilities to use isothermal chemistry.
  • The MiQLab System can now successfully detect Leptospira DNA in as little as 30 minutes when processing urine spiked with Leptospira genetic material.
  • The MiQLab System has the capabilities to detect these troublesome bacteria in as soon as 30 minutes without needing to culture.
  • At this time, we are aiming to have positive results available in as soon as 30 minutes, whereas negative results might not be available for 40+ minutes.

Global Otoscopes Market Research Report 2022: Market to Reach $198.1 Million by 2026 - US and Europe Dominate the Market

Retrieved on: 
Wednesday, August 24, 2022
Machine learning, ENT, Audiology, Technology, Ear canal, Eardrum, Hearing loss, Brain, Internet, Computer, Polypharmacy, Problem solving, Incidence, Learning, Quality of life, Otitis media, Artificial intelligence, Prevalence, CAGR, Kool-Aid, Communication, Rubella, Injury, Meningitis, Growth, AI, Pregnancy, Mumps, Pet, Medical device, Mobile phone, Video game, Otoscope

DUBLIN, Aug. 24, 2022 /PRNewswire/ -- The "Otoscopes - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 24, 2022 /PRNewswire/ -- The "Otoscopes - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Otoscopes estimated at US$172.8 Million in the year 2022, is projected to reach a revised size of US$198.1 Million by 2026, growing at a CAGR of 3.2% over the analysis period.
  • Pocket-size Otoscopes, one of the segments analyzed in the report, is projected to record a 2.9% CAGR and reach US$89.4 Million by the end of the analysis period.
  • The U.S. Market is Estimated at $60.4 Million in 2022, While China is Forecast to Reach $14 Million by 2026
    The Otoscopes market in the U.S. is estimated at US$60.4 Million in the year 2022.

GC Biopharma to Present New Data on Trends in Varicella Incidence Cases with Complications Among Korean Children at the 2022 ICPE

Retrieved on: 
Wednesday, August 24, 2022
Biotechnology, Infectious Diseases, Other Health, Health, Pharmaceutical, ICPE, Vaccination, Ageing, Green Cross, Vaccine, Pneumonia, Encephalomyelitis, Incidence, Person, Encephalitis, Knowledge Organization (journal), Department, Doctor of Science, Chickenpox, Conference, Therapy, GC, 2021 Essex County Council election, Biopharma LLC, Meningitis, International Conference of Physics Students, Myelitis, Research

GC Biopharma (006280.KS) today announced that it will present new data demonstrating trends in the incidence of varicella cases with complications among Korean children during 2010-2020 after the universal one-dose varicella vaccination program.

Key Points: 
  • GC Biopharma (006280.KS) today announced that it will present new data demonstrating trends in the incidence of varicella cases with complications among Korean children during 2010-2020 after the universal one-dose varicella vaccination program.
  • The results show that varicella incidence cases with complications among Korean children significantly (92%) decreased from 137 per 100,000 persons in 2010 to 11 per 100,000 persons in 2020.
  • In the sub-analyses, the decrease in the incidence of varicella cases with complications was greater in children aged 0-4 (96%) and aged 5-9 (92%) than in children aged 10-19 (77-78%).
  • In addition, this study indicates that the universal one-dose varicella vaccination program introduced in 2005 has been successful in preventing severe incident varicella cases among Korean children.

Global Otoscopes Market Research Report 2022: AI-Powered Otoscopy Makes Headway in the Market - ResearchAndMarkets.com

Retrieved on: 
Monday, August 22, 2022
Medical Devices, Health, Machine learning, ENT, Audiology, Technology, Ear canal, Eardrum, Hearing loss, Brain, Internet, Computer, Polypharmacy, Problem solving, Incidence, Learning, Quality of life, Otitis media, Artificial intelligence, Prevalence, CAGR, Kool-Aid, Communication, Rubella, Injury, Meningitis, Growth, AI, Pregnancy, Mumps, Pet, Medical device, Mobile phone, Video game, Otoscope

The "Otoscopes - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Otoscopes - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • In the global Video Otoscopes segment, USA, Canada, Japan, China and Europe will drive the 3.4% CAGR estimated for this segment.
  • The market growth is also facilitated by availability of rechargeable, user-friendly pocket otoscopes along with increasing number of otolaryngology professionals.
  • Rising incidence of hearing loss is also expected to drive the global otoscopes market in the long-term.

Global Central Nervous System Partnering Deals Directory 2022: Trends, Players and Financials for 1,700+ Deals Signed Since 2015 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 18, 2022
Health, Other Health, Parkinson's disease, Restless legs syndrome, Disease, CNS, Directory, Technology, Dizziness, SEC, Finance, Chapter Four, Multiple sclerosis, Chapter Five, Central nervous system, Chapter Three, Haemophilus influenzae, Restless, Guillain–Barré syndrome, Review, Stroke, Contract, Traumatic brain injury, Amyotrophy, Players, Bacteria, Peripheral neuropathy, Weakness, Chapter Six, Cerebral palsy, Chapter One, Chapter Two, Vertigo, Hyperlink, Migraine, Peripheral nervous system, Spinal cord, Creutzfeldt–Jakob disease, Headache, Mycobacterium tuberculosis, Sclerosis (medicine), TB, A-Z, Pharmaceutical industry, Bank, Risk management, Petroleum, Nausea, Stuttering, Fibromyalgia, Meningitis, Epilepsy, Paralysis, Neuralgia, Pain, Haemophilus

The Global Central Nervous System Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 1,700 central nervous system deals.

Key Points: 
  • The Global Central Nervous System Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 1,700 central nervous system deals.
  • The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.
  • Chapter 6 provides a comprehensive directory of all Central Nervous System partnering deals by specific Central Nervous System target announced since 2015.
  • Global Central Nervous System Partnering 2015 to 2022 includes:
    In Global Central Nervous System Partnering 2015 to 2022, available deals and contracts are listed by:

QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency

Retrieved on: 
Monday, August 15, 2022
Health, Infectious Diseases, Clinical Trials, Research, Pharmaceutical, Science, U.S. Securities and Exchange Commission, Â, Monkeypox, Union, Public health, Laboratory, World Health Organization, Budget, VZV, NYSE, Senior, HSV2, Growth, SEC, Research, Life, Government, Blood, European, DNA, COVID-19, Infection, Urinary tract infection, QIAGEN, List of life sciences, HH6, RNA, RUO, Gold standard (test), Herpes labialis, Enterovirus, Knowledge, WHO, World, Automation, QGEN, Meningitis, Protein, Monkeypox virus, Molecular diagnostics, PCR, Solution, LDT, HSV1, Vaccine, Pharmaceutical industry, Insight

The new panel currently for research use only (RUO) comes in cartridge form to run on QIAGENs QIAstat-Dx automated syndromic testing devices.

Key Points: 
  • The new panel currently for research use only (RUO) comes in cartridge form to run on QIAGENs QIAstat-Dx automated syndromic testing devices.
  • Currently the worlds only syndromic test for the pathogen, the panel will prove to be crucial for detecting and then combatting the spread of monkeypox around the globe.
  • The panels RUO-status means it currently can only be used for the surveillance not screening or diagnosing of monkeypox cases.
  • QIAGEN teams around the world are working with healthcare authorities to support testing for the monkeypox virus outbreak.

Flu Shots Are Now Available at Walgreens Nationwide for Everyone Aged 3 and Up

Retrieved on: 
Monday, August 15, 2022
Men, Other Retail, Pharmaceutical, Specialty, Consumer, Infectious Diseases, Parenting, Retail, Children, Women, Seniors, Health, Multimedia, Ageing, Cough, Polio, Pharmacy, Pneumonia, Technology, Shingles, Department, Walgreens Boots Alliance, Influenza, Patient, Health department, COVID-19, Fever Dream, WBA, Program, Vaccine, Parent, United Nations Foundation, Immunization, Department of Health (Australia), Vaccination, Doctor of Pharmacy, Meningitis, Insurance, Nasdaq, UN, Tetanus, Measles, Minor, Health, Ministry, Pharmacist, Pharmaceutical industry, Walgreens

Walgreens is now offering flu shots for anyone aged 3 years and up at nearly 9,000 store locations nationwide to help reduce the spread of vaccine-preventable illnesses in communities.

Key Points: 
  • Walgreens is now offering flu shots for anyone aged 3 years and up at nearly 9,000 store locations nationwide to help reduce the spread of vaccine-preventable illnesses in communities.
  • To help save families a trip, Walgreens pharmacists are co-administering flu shots and other recommended vaccines during a single visit.
  • Walgreens is offering a $5 Walgreens Cash reward in August through December and a $10 Walgreens Cash reward* during the month of September to individuals who receive any vaccination at a Walgreens location.
  • To schedule an appointment for a flu shot or any vaccine at Walgreens, please visit Walgreens.com/ScheduleVaccine or download the Walgreens app.

Largest Study of Brain Tumor "Keyhole" Surgery for Meningiomas

Retrieved on: 
Thursday, August 4, 2022
Meningioma, Hospital, Risk, Radiosurgery, Endoscopy, Human skull symbolism, PNI, Brain, Myocardial infarction, Providence High School, Patient, Embolism, Publication, Cerebrospinal fluid leak, PLOS, Meningitis, MD, Saint John's Health Center, Blood, Neuro, Time, St. Mary's Medical Center (Grand Junction, Colorado), Cranial nerves, Medical imaging, Pharmaceutical industry

SANTA MONICA, Calif., Aug. 4, 2022 /PRNewswire/ -- In a groundbreaking 13-year study, Pacific Neuroscience Institute neurosurgical and otolaryngology surgical teams demonstrated outstanding outcomes with minimally invasive keyhole surgery for the most common primary brain tumor, in the largest such keyhole cohort published to date.

Key Points: 
  • "Patients coming to us with brain tumors are understandably worried about their diagnoses and clinical outcomes," said neurosurgeon Daniel Kelly, MD, PNI director and senior author of the study.
  • "Keyhole surgery aims to limit brain exposure and manipulation, using smaller strategically placed openings without the use of brain retractors and facilitated by gravity assistance and endoscopy.
  • Meningiomas, the most common primary brain tumor, are non-cancerous brain tumors estimated to be diagnosed in approximately 34,000 people in the United States each year.
  • From an overall cohort of 329 patients with meningiomas treated from 2008-21, the study focused on 193 (59%) who underwent 213 keyhole operations.

Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Retrieved on: 
Thursday, August 4, 2022
U.S. Securities and Exchange Commission, GLOBE, Death, SEC, Success, Streptococcus, Security (finance), Communication, Plasma protein binding, Patient, Infection, PCV, Peterborough, Periodontal disease, Collection, Streptococcus pneumoniae, IPD, Overalls, Food, Disease, Immunodeficiency, Fast track (FDA), Sinusitis, SAN, Safety, Priority review, Meningitis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Trial of the century, Mortality, Pneumonia, Incidence, Subclinical infection, Vaccine, Vaccination, Genetically modified bacteria, Chemistry, Fast Track, FDA, Sutro Biopharma, Private Securities Litigation Reform Act, Population, PD, IND, Separate, Ageing, Achievement, Pneumococcal conjugate vaccine, Review, Otitis media, Company, Bacteria, Â, Drug discovery, Antigen, Pharmaceutical industry, COVID-19

SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VAX-24, the Company’s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in adults ages 18 and older. The Fast Track designation is an FDA process that has been designed to facilitate the development and expedite the review of drugs, including vaccines, that treat or prevent serious conditions and fill an unmet medical need.

Key Points: 
  • The Company also completed a successful pre-Investigational New Drug (IND) meeting with the FDA regarding the VAX-24 pediatric program.
  • Vaxcyte is deploying this approach with VAX-24 in order to add more pneumococcal strains without compromising the overall immune response.
  • Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases.
  • Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

The Caring Foundation of Texas to offer free vaccinations to students in DFW, Houston regions

Retrieved on: 
Monday, August 1, 2022
Fair Park, Health education, Blue Shield, School, HPV, Plano, California Health Care Foundation, National Immunization Technical Advisory Group, Health, Dental care, COVID-19, Multimedia, Vaccine, DFW, PlazAmericas, Immunization, Vaccination, Blue Cross, Grand, Program, Meningitis, Hygiene, Fashion, Communications satellite, Health insurance, Bellaire Boulevard

RICHARDSON, Texas, Aug. 1, 2022 /PRNewswire/ -- Efforts to bridge immunization gaps caused by the COVID-19 pandemic and decreased preventative health visits is top of mind this year as the The Caring Foundation of Texas ramps up free vaccination opportunities across Texas to facilitate back-to-school readiness and facilitate health education during National Immunization Awareness month.

Key Points: 
  • The Caring Foundation will deploy its Care Van Program to Dallas and Houston area schools and community centers to provide the vaccinations.
  • The following Care Van events have been scheduled in Dallas and Houston, but check the Caring Foundation'scalendar for updates as dates and times can change.
  • Since 1997, the Care Vans have provided more than 1.4 million vaccinations to children across Texas.
  • Established in 1991, The Caring Foundation of Texas is a 501(c)3 organization, funded by community contributions, corporate sponsorships, grants and in-kind donations.